MYO-029

 

Topic mentions per year

Topic mentions per year

2006-2015
01220062015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Suppression of the myostatin (GDF-8) pathway has emerged as an important therapeutic paradigm for muscle-wasting disorders. In… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2016
2016
RATIONALE A plethora of compounds potentially leading to drug candidates that affect skeletal muscle function and, more… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
INTRODUCTION Facioscapulohumeral muscular dystrophy (FSHD) is a hereditary disorder that causes progressive muscle wasting… (More)
Is this relevant?
2011
2011
Myostatin, a member of the muscle-specific transforming growth factor (TGF)-β family, negatively regulates skeletal muscle growth… (More)
Is this relevant?
2011
2011
Myostatin, a member of the muscle-specific transforming growth factor (TGF)-β family, negatively regulates skeletal muscle growth… (More)
Is this relevant?
2009
2009
Myostatin inhibitors are being investigated as treatments for myopathies. We assessed single muscle fiber contractile properties… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2009
2009
UNLABELLED Methodological problems, including binding of myostatin to plasma proteins and cross-reactivity of assay reagents with… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
OBJECTIVE Myostatin is an endogenous negative regulator of muscle growth and a novel target for muscle diseases. We conducted a… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2006
2006
Myostatin is a member of the TGF-beta superfamily that is expressed predominantly in skeletal muscle and functions as a negative… (More)
Is this relevant?